Company Snapshot
- Ticker
- BIIB
- Name
- BIOGEN INC
- Sector
- Healthcare
- Currency
- USD
- Relative Volume
- 1.92
- Market Cap
- 18001
- Volume
- 3,088,294
- Avg Volume (3M)
- 1,610,344
BIIB
BIOGEN INC
Last update recent
177.51
+1.67
(+0.95%)
Market Cap
18001
Dividend Yield
0.00%
1Y Return
-40.41%
Beta
0.43
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 9675900000
- EPS
- 11.18
- Dividend / Share
- 0.0
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- 1,632,200,000
- Net Margin
- 16.87%
- Payout Ratio
- 0.0
- Qtly Growth YoY
Valuation & Quality
- P/E
- 11.0
- Forward P/E
- P/S
- 1.9
- P/B
- 1.1
- Beta
- 0.43
- Debt / Equity
- 0.68
- Current Ratio
- 1.35
- Return on Equity
- 10.2%
- Return on Assets
- 5.9%
Technicals & Returns
- Distance vs 200 DMA
- -29.9%
- 200 DMA
- 175.43
- Distance vs 50 DMA
- -12.69%
- 50 DMA
- 140.86
- Return 1Y
- -40.41%
- Return YTD
- -19.58%
- Beta (Trailing)
- 0.43
- Relative Volume
- 1.92
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimil Read more
- Name
- BIOGEN INC
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Christopher A. Viehbacher
- Employees
- 7,570
- IPO Date
- 1991-09-17
- Phone
- (617) 679-2000
- Address
- 225 Binney Street, Cambridge, MA
- Website
- https://www.biogen.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
Biogen Inc. $BIIB Shares Purchased by Balyasny Asset Management L.P.
Balyasny Asset Management L.P. raised its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 5.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 831,905 shares of the biotechnology company's stock after purchasing an additional 45,686 shares during
Biogen Inc. $BIIB Shares Sold by Daiwa Securities Group Inc.
Daiwa Securities Group Inc. lessened its holdings in Biogen Inc. (NASDAQ: BIIB) by 9.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,128 shares of the biotechnology company's stock after selling 4,265 shares during the quarter. Daiwa Securities Group Inc.'s holdings
Federated Hermes Inc. Acquires 17,069 Shares of Biogen Inc. $BIIB
Federated Hermes Inc. raised its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 16.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 120,277 shares of the biotechnology company's stock after purchasing an additional 17,069 shares during the quarter. Federated
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More
Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor a 25-basis-point rate hike. The worry hanging over traders is that many fear a "hawkish rate cut." Where they do cut 25 basis... Here Are Wednesday's Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More.
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-A? protofibril* antibody “LEQEMBI®” (brand name in China: “???®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: ????????????), recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China.
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life—